ASCO strongly opposes the Centers for Medicare & Medicaid Services (CMS) decision to allow Medicare Advantage plans to employ step therapy across physician-administered and self-administered drugs under Medicare Part B and Part D.
ASCO strongly opposes provisions in the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule that could significantly cut cancer care resources that are needed to provide high-quality care to individuals with cancer.
Today at the 2018 ASCO Annual Meeting, National Cancer Institute (NCI) Director Norman Sharpless, MD, announced $10 million in new funding for the National Clinical Trials Network (NCTN). ASCO applauds Dr. Sharpless' leadership in ensuring NCI's continued commitment to clinical trials, which expand our knowledge of cancer and offer the best treatment options for many patients.
As nearly 40,000 oncology professionals from around the world gather in Chicago for the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) to learn about the latest in clinical cancer research -- from new treatment options and advances in precision medicine to insight for improving access to care -- ASCO welcomes the U.S. Food and Drug Administration's (FDA) announcement that it is advancing new policies to make the drug review and approval process more modern, more scientifically rigorous, and more efficient.
The American Society of Clinical Oncology (ASCO) announced today that Trevor Royce, MS, MD, MPH, and Sheetal Kircher, MD, have been selected for the ASCO Health Policy Fellowship Program. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge-base, skills, and experience necessary to shape regulatory and legislative policies that directly affect the practice environment and impact patients with cancer and their care teams.
Alexandria, Va. – An analysis published today in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice (JOP), suggests that including cancer drug costs in bundled payments under Medicare risks destabilizing the cancer care delivery environment. According to the report, Medicare reimbursement would vary widely in such a model depending on the mix of patient conditions practices treat, rather than the quality of care they provide—with reimbursement to practices that see a large volume of complex patients declining significantly from current levels.
The American Society of Clinical Oncology (ASCO) applauds Congress for its bipartisan support of the omnibus spending bill that significantly boosts our nation's investment in biomedical research. By providing a $3 billion funding increase for the National Institutes of Health (NIH) for fiscal year (FY) 2018—the biggest NIH funding increase in 15 years—Congress has taken bold action to regain much-needed momentum in cancer research following a decade of stagnant funding for the NIH.
ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study
Statement from Bruce E. Johnson, MD, FASCO, President of the American Society of Clinical Oncology (ASCO)
The American Society of Clinical Oncology (ASCO) commends Congress for passing a continuing resolution that includes an important correction to the Merit-based Incentive Payment System. We are also pleased to see a budget deal that commits to at least a $2 billion funding increase for the National Institutes of Health (NIH) to reclaim America’s leadership in cancer research and continue building on our tremendous progress towards understanding, preventing, and treating cancer.
The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.
"Over the past few decades we’ve seen global cancer death rates drop thanks to dramatic improvements in diagnosis and treatment. But the unfortunate reality is that millions of patients worldwide are not yet reaping the benefits of the progress we’ve made because of inability to access care. All too often, where someone lives dictates their chances of surviving cancer."
The American Society of Clinical Oncology (ASCO) congratulates Alex Azar for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). As the head of HHS, Secretary Azar has an opportunity to help address critical issues facing the cancer care delivery system, including increasing access to high-quality care, addressing the high cost of care, and supporting the development and dissemination of innovative treatments
With the Tax Cuts and Jobs Act on the verge of being signed into law, the American Society of Clinical Oncology (ASCO) is concerned about across-the-board cuts to Medicare that the measure will trigger. We urge Congress to protect Medicare beneficiaries with cancer and other medical conditions by passing additional legislation to avoid cuts to the program.
We are deeply concerned about the sequestration cuts that would be triggered by passage of the Tax Cuts and Jobs Act. The core mission of the American Society of Clinical Oncology (ASCO) is to ensure that cancer patients have meaningful access to high-quality cancer care. We fear that the current proposal will harm patients with cancer by reducing access to care, a situation that could adversely impact treatment needed to extend and save patients' lives.
A report released today by the National Academies of Sciences, Engineering, and Medicine underscores the imperative our nation faces to address the affordability of drugs for medical conditions that have long-been deemed untreatable. Nowhere is this imperative more urgent than with the new generation of cancer drugs that is giving hope to the millions of Americans who face a cancer diagnosis each year--while creating formidable barriers to access due to the high cost of these agents.